期刊文献+

盐酸洛拉曲克长循环脂质体的制备及其对肝癌细胞的体外毒性 被引量:3

下载PDF
导出
摘要 目的:研制出具有缓释作用的盐酸洛拉曲克长循环脂质体并考察其理化特性以及在体外的抗瘤效应.方法:用两亲性聚乙二醇-二硬脂酰磷脂酰乙醇胺(PEG-DSPE)对脂质体膜进行修饰,以薄膜挤压-硫酸铵梯度法制备盐酸洛拉曲克长循环脂质体;用MTT法比较盐酸洛拉曲克长循环脂质体与盐酸洛拉曲克普通脂质体及游离的盐酸洛拉曲克的体外细胞毒性.结果:制备的盐酸洛拉曲克隐形脂质体包封率达68%左右,粒径110nm左右;与普通脂质体及游离的盐酸洛拉曲克相对照,长循环脂质体显示了较好长效的毒性作用,2h组长循环脂质体的ID50明显高于另外两组,而48h组的ID50则与另外两组无显著差别.结论:新制备的盐酸洛拉曲克长循环脂质体在体外显示了其较好的缓释效应,可以弥补盐酸洛拉曲克在体内半衰期比较短的缺点.
出处 《世界华人消化杂志》 CAS 北大核心 2005年第11期1346-1348,共3页 World Chinese Journal of Digestology
基金 全军医药卫生科研指令性课题 No.04T101
  • 相关文献

参考文献14

  • 1Stout TJ, Stroud RM. The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2. 0 A resolution: Implication for a new mode of inhibition. Structure 1996;4:67-77
  • 2Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H, Seeber S. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997;15:389-400
  • 3Schiffer CA, Clifton IJ, Davisson VJ, Santi DV, Stroud RM.Crystal structure of human thymidylate synthase: a structural mechanism for guiding substrates into the active site. Biochemistry 1995;34:16279-16287
  • 4Sakoff JA, Howitt IJ, Ackland SP, McCluskey A. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition. Cancer Chemother Pharmacol 2004;53:225-232
  • 5Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, Taylor GA, Rafi I, Hughes AN, Calvert AH, Price PM, Newell DR. 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst 2003;95:675-682
  • 6Mok TS, Leung TW, Lee SD, Chao Y, Chan AT, Huang A, Lui MC, Yeo W, Chak K, Johnston A, Johnson P. A multi-centre randomized phase II study of nolatrexed Versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 1999;44:307-311
  • 7Staurt K, Tessitore J, Rudy J, Clendinnen N, Johnston A. A phaseⅡ trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer 1999;86:410-414
  • 8Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003;42:463-478
  • 9Bakker-Woudenberg IA. Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious foci. Int J Antimicrob Agents 2002;19:299-311
  • 10Kallinteri P, Fatouros D, Klepetsanis P, Antimisiaris SG. Arsenic trioxide liposomes: encapsulation efficiency and in vitro stability. J Liposome Res 2004;14:27-38

同被引文献54

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部